A Randomized, Double -Blind, Placebo-Controlled, Sequential, Multiple-Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Subjects With Moderate-To-Severe Atopic Dermatitis
Latest Information Update: 27 Feb 2023
At a glance
- Drugs Gusacitinib (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Proof of concept
- Sponsors Asana BioSciences; Kirilys Therapeutics
- 26 Jul 2019 Results published in the Journal of Allergy and Clinical Immunology.
- 28 Mar 2019 Results assessing efficacy, safety, pharmacokinetics and on systemic biomarkers of ASN002, published in the British Journal of Dermatology.
- 19 Jul 2018 According to an Asana BioSciences media release, Dr. Robert Bissonnette is the President of Innovaderm Research, Montreal, Canada and a lead investigator for the ASN002 Phase 1b and Phase 2b RADIANT study.